Related by context. All words. (Click for frequent words.) 81 Meets Primary Endpoint 80 Prolongs Survival 80 Improves Survival 79 Newly Diagnosed Multiple Myeloma 79 Oral Fingolimod 79 Advanced Melanoma 79 Novel Oral 79 Chronic Hepatitis C 79 Patients Treated With 78 Combination Treatment 78 Drug Candidate 78 Study Evaluating 78 Phase 2b Clinical Trial 78 Receives Orphan Drug Designation 78 Clinical Trial Results 78 Improves Outcomes 78 Completes Patient Enrollment 77 Pulmonary Arterial Hypertension 77 Rheumatoid Arthritis Patients 77 Adjuvant Treatment 77 Chronic Hepatitis B 77 Adjuvant Chemotherapy 77 Previously Treated 77 Demonstrates Significant 77 Long Term Efficacy 77 Phase IIb Trial 77 Antitumor Activity 77 Relapsing Multiple Sclerosis 77 Subgroup Analysis 77 Pivotal Phase III 77 Metastatic Colorectal Cancer 77 Investigational Compound 77 Initiates Phase III 77 Survival Benefit 76 Investigational Treatment 76 JAK Inhibitor 76 Improved Survival 76 Relapsed Refractory 76 Phase III Trial 76 Patients Receiving 76 Is Well Tolerated 76 Improve Survival 76 Phase IIb Clinical Trial 76 Randomized Phase 76 Shows Efficacy 76 Completes Enrollment 76 Progressive Multifocal Leukoencephalopathy 76 Treatment Experienced 76 Complicated Skin 76 Phase 2b Study 76 Fungal Infections 76 HER2 Positive Breast Cancer 76 Initiates Clinical Trial 76 Breast Cancer Recurrence 76 Phase III Clinical Trial 76 FDA Approvals 76 Disease Progression 76 Pooled Analysis 76 Phase 2b Trial 76 Clinical Trial Evaluating 76 Combination Therapy 76 Initiate Phase 76 Hormone Refractory Prostate Cancer 76 Files IND 76 Well Tolerated 76 Initiates Enrollment 75 Demonstrates Positive 75 Patients Treated 75 Overactive Bladder 75 Renal Cell Carcinoma 75 Combination REOLYSIN R 75 Heart Failure Patients 75 Pivotal Phase 75 Mylan Receives Approval 75 Diabetic Patients 75 SPRYCEL ® 75 Rotavirus Vaccine 75 Single Dose 75 Safinamide 75 Pivotal Trial 75 Elderly Patients 75 Myeloma Patients 75 Chronic Myeloid Leukemia 75 Cutaneous T 75 Initiates Phase II 75 Recombinant Human 75 Tyrosine Kinase Inhibitor 75 Shows Promising 75 Teva Provides Update 75 JAK2 Inhibitor 75 Advanced Colorectal Cancer 75 Investigational Agent 75 Treatment Naïve 75 Diabetic Nephropathy 75 Pivotal Study 75 FDA APPROVES 75 Myelodysplastic Syndromes 75 Acute Ischemic Stroke 75 Phase IIa Clinical Trial 75 Hepatocellular Carcinoma 75 Preclinical Models 75 Epilepsy Drug 75 Patient Enrollment 74 Inhaled Corticosteroids 74 Proves Effective 74 Previously Untreated 74 NDA Submission 74 Phase 2a Trial 74 Soft Tissue Sarcoma 74 Clinical Outcome 74 Renal Cancer 74 Phase 2a Clinical Trial 74 Submits NDA 74 Acute Myocardial Infarction 74 Chronic Lymphocytic Leukemia 74 Drug Shows Promise 74 Patients Undergoing 74 Liver Failure 74 Colorectal Cancer Patients 74 Randomized Double Blind 74 Bosutinib 74 Lung Cancer Patients 74 Randomized Study 74 Nicotine Vaccine 74 Randomized Clinical Trial 74 Shows Promise Against 74 Drug Fails 74 FDA Okays 74 Nilotinib 74 HCV Protease Inhibitor 74 Mouse Model 74 Initiate Clinical Trial 74 Castration Resistant Prostate Cancer 74 Treatment Naive Patients 74 Investigational Drug 74 Preclinical Data 74 RNAi Therapeutic 74 Predict Risk 74 IND Filing 74 Resistant Hypertension 74 Adjuvant Therapy 74 Gastric Cancer 74 Pivotal Clinical Trial 74 Monotherapy 74 Ischemic Stroke 74 First Patient Enrolled 74 Granted Orphan Drug 74 Plaque Psoriasis 74 Myelodysplastic Syndrome MDS 74 Malignant Melanoma 74 Oral Mucositis 74 Chronic Sinusitis 74 Presents Preclinical Data 74 Dose Finding 74 Tigecycline 74 Trial Evaluating 74 Advanced Prostate Cancer 74 IND Application 74 II Clinical Trial 74 Node Positive 74 Autologous Stem Cell Transplantation 74 Peginterferon Alfa 2a 74 Osteoporosis Drug 74 Atypical Hemolytic Uremic Syndrome 73 Hormone Receptor Positive 73 Reduces Mortality 73 Anticancer Activity 73 Venous Thromboembolism 73 Inhaled Insulin 73 Cholesterol Lowering Drug 73 Chronic Heart Failure 73 Slow Progression 73 Presents Positive 73 Adjunctive Therapy 73 R lenalidomide 73 Myelofibrosis 73 Randomized Phase II 73 Renal Function 73 Recurrent Glioblastoma 73 Arthritis Drug 73 Statistically Significant 73 Confirmatory Phase 73 Lupus Nephritis 73 Initiates Clinical 73 Mg Usa 73 Gout Drug 73 Successfully Completes Phase 73 Diabetic Neuropathy 73 Randomized Clinical Trials 73 Protease Inhibitor 73 Fondaparinux 73 Septic Shock 73 First Patient Dosed 73 Treated Patients 73 Begins Dosing 73 achieved CCyR 73 Drug Resistant 73 Relapsing Remitting Multiple Sclerosis 73 Metastatic Prostate Cancer 73 Hsp# Inhibitor 73 Prostate Cancer Patients 73 FDA Accepts 73 Unfractionated Heparin 73 Demonstrated Significant 73 Controlled Trial 73 Hypertensive Patients 73 Multiple Myeloma Patients 73 Novel Antibiotic 73 Drug Combo 73 Leukemias 73 Study Showed 73 Acute Decompensated Heart Failure 73 Postmenopausal Women 73 Pediatric Patients 73 metastatic malignant 73 Metastatic Melanoma 73 Bone Metastases 73 Lupus Drug 73 Knee Osteoarthritis 73 Combo Therapy 73 dasatinib Sprycel ® 73 Heterozygous Familial Hypercholesterolemia 73 Anti Tumor Activity 73 Dose Escalation 73 Lung Cancer Drug 73 Acute Heart Failure 73 Pharmacokinetics PK 73 Sustained Efficacy 73 Randomized Controlled Trials 73 Expanded Indication 73 Prostate Cancer Vaccine 73 Follicular Lymphoma 73 J Am Coll 73 Phase III Trials 73 Demonstrates Potent 73 Prospective Randomized 73 Orally Active 73 Hematological Malignancies 73 Successfully Treated 73 See CLINICAL PHARMACOLOGY 73 Pneumococcal Vaccine 73 Appears Safe 73 Fixed Dose 73 Treating Chronic 73 Chemoradiation 73 Hepatitis B Vaccine 73 Tiotropium 73 Hemodialysis Patients 73 Boosts Survival 72 Invasive Breast Cancer 72 Confirms Efficacy 72 Peginterferon 72 Achieves Primary Endpoint 72 Inflammatory Markers 72 Infected Patients 72 Hospital Acquired Pneumonia 72 Preclinical Study 72 Cardiovascular Events 72 Anticancer Drug 72 Diabetic Foot Ulcer 72 Files Investigational 72 Generic Version 72 Pharmacokinetic Study 72 TB Vaccine 72 Refractory Hodgkin Lymphoma 72 Chronic Renal Failure 72 Kidney Transplant Patients 72 alfa 2a 72 Parathyroid Hormone 72 Schizophrenia Treatment 72 Vaccine Adjuvant 72 Blood Pressure Drug 72 Solid Tumors 72 Treatment Naive HIV 72 Unstable Angina 72 Severe Asthma 72 Lowers Risk 72 Newly Diagnosed Patients 72 Anthracycline 72 PRN FDA Approves 72 Dose Ranging Study 72 Novel Inhibitor 72 Premature Infants 72 Decitabine 72 Relapsed Multiple Myeloma 72 Benign Prostatic Hyperplasia 72 Present Preclinical Data 72 Gets FDA Clearance 72 Metastatic Renal Cell Carcinoma 72 Antitumor 72 Cholesterol Drug 72 Artery Disease 72 Transdermal Patch 72 Tumor Growth 72 Immunotherapeutic 72 FDA Clears 72 Hepatitis C Genotype 72 sunitinib Sutent 72 Gene Linked 72 Data Suggest 72 Treatment Reduces 72 Mg Uk 72 Significantly Improves 72 Acute Coronary Syndromes 72 Brain Metastases 72 Brentuximab Vedotin SGN 72 Kinase Inhibitor 72 First Patient Treated 72 Stem Cell Treatment 72 Allogeneic 72 Critically Ill Patients 72 Platelet Inhibition 72 Recurrent Breast Cancer 72 Pafuramidine 72 Dendritic Cells 72 TO AVOID PREGNANCY WHILE 72 Advanced Renal Cell 72 Nebulized 72 FDA Approves Drug 72 Plus Ribavirin 72 Demonstrates Potential 72 Anticoagulant 72 Genes Predict 72 Immunomedics Announces 72 Psoriasis Drug 72 Postmenopausal Osteoporosis 72 Chronic Constipation 72 Ovarian Cancer Patients 72 Fast Track Status 72 Anti Tumor 72 Lung Cancer Trial 72 Rheumatoid Arthritis Drug 72 Pegylated Liposomal Doxorubicin 72 Hepatitis C Virus 72 Ranolazine 72 Phase 1b Clinical Trial 72 Initiate Phase III 72 Fewer Side Effects 72 ACE Inhibitors 72 Treatment Resistant 72 Effectively Treats 72 Significantly Reduces 72 Allergic Rhinitis 72 Cardiotoxicity 72 Receives Positive Opinion 72 Malignant Glioma 72 myelodysplastic myeloproliferative diseases 72 Endometrial Cancer 71 Initiates Clinical Trials 71 Breast Cancer Treatment 71 Treatment Shows Promise 71 Serious Infections 71 Hypercholesterolemia 71 Intravenous Formulation 71 Stent Thrombosis 71 Gene Variant 71 Stent Restenosis 71 Versus Placebo 71 Gene Mutation 71 ORENCIA ® 71 dual endothelin receptor antagonist 71 Positive Opinion 71 Treat Anemia 71 Treatment Naive 71 Crit Rev 71 Non Alcoholic Steatohepatitis 71 Cancer Incidence Mortality 71 TNF Blockers 71 Showed Significant 71 Demonstrates Efficacy 71 Initiates Dosing 71 Diabetic Foot Ulcers 71 Patients Suffering 71 Controlled Study 71 Juvenile Idiopathic Arthritis 71 Respiratory Distress 71 Clinical Trial Data 71 Levels Linked 71 Significantly Improved 71 Tezampanel 71 Cell Transplants 71 Acute Renal Failure 71 Aurora Kinase 71 Bronchiectasis 71 Cognitive Impairment 71 Pegylated Interferon 71 Demonstrates Sustained 71 Carotid Stenting 71 Interferon Beta 71 ST Segment Elevation 71 Localized Prostate Cancer 71 Study Demonstrates 71 Proven Effective 71 Gene Variants 71 refractory chronic lymphocytic 71 Cancer Patients Treated 71 Reduced Risk 71 Cardiovascular Outcomes 71 Slows Progression 71 Eluting Stent 71 NICE Recommends 71 Secondary Hyperparathyroidism 71 Glatiramer Acetate 71 Enlarged Prostate 71 Novel Treatments 71 Vidaza ® 71 Schizophrenia Drug 71 Immune Responses 71 Unresectable 71 Kidney Function 71 Patient Outcomes 71 Placebo Controlled Trial 71 Thromboembolism 71 Diabetic Macular Edema 71 Non Alcoholic Fatty 71 Bare Metal Stents 71 Intracerebral Hemorrhage 71 Oral Calcitonin 71 Mycophenolate Mofetil 71 Drug Prevents 71 Sipuleucel T 71 Increases Risk 71 Prognostic Significance 71 Submits Supplemental 71 Receives Milestone Payment 71 Sprycel dasatinib 71 hypereosinophilic syndrome 71 Beta Blocker 71 Attenuates 71 Vicriviroc 71 Osteoporosis Treatment 71 Orthop Surg 71 Antiplatelet 71 Earns Milestone Payment 71 Neoadjuvant 71 Phase Ib Clinical Trial 71 Systemic Sclerosis 71 Treating Heart Failure 71 chronic eosinophilic leukemia 71 adalimumab Humira 71 Potentially Fatal 71 Nesiritide 71 ST Elevation Myocardial 71 Abstract Accepted 71 Cocaine Addiction 71 Dose Ranging 71 Antigen Specific 71 Statin Drugs 71 Neoadjuvant Chemotherapy 71 Chronic Bronchitis 71 Cell Lymphoma 71 IN PATIENTS WITH 71 induced macular edema 71 familial amyloidotic polyneuropathy FAP 71 Anemia Drug 71 Fracture Risk 71 complement inhibitor eculizumab 71 Spectrum Pharmaceuticals Announces 71 Bipolar Mania 71 Pegloticase 71 Diffuse Large B 71 Patients Enrolled 71 Stem Cell Transplants 71 Obese Patients 71 methylnaltrexone bromide 71 Risk Stratification 71 Commences Phase 70 Prophylactic Treatment 70 Dual Antiplatelet Therapy 70 Tumor Response 70 Glufosfamide 70 #-# Full Text 70 Insulin Glargine 70 Ischemic 70 Sangamo BioSciences Announces 70 Efficacy Results 70 brand ciclesonide HFA 70 Chronic Insomnia 70 Left Ventricular 70 Initiates Phase 2b 70 Respiratory Virus 70 Aflibercept 70 Epidermal Growth Factor Receptor 70 Omacetaxine 70 Paraplatin ® 70 Etanercept 70 Newly Diagnosed 70 Bucindolol 70 Bazedoxifene 70 Medoxomil 70 Prostate Cancer Treatment 70 Kidney Failure 70 Clinical Efficacy 70 insulin glulisine 70 Low Dose 70 Fabry Disease 70 TRANSDUR ® 70 Epoetin Alfa 70 Vaccine Protects Against 70 Predict Response 70 Osteoporosis Drugs 70 Phase III Pivotal 70 HER2 Positive 70 Clostridium difficile Infection 70 Genes Linked 70 Inhaled Nitric Oxide 70 Nonalcoholic Fatty Liver Disease 70 Cypher Sirolimus 70 Emerging Therapies 70 Transplant Patients 70 Epratuzumab 70 Romiplostim 70 Efficacy Trial 70 Patient Enrolment 70 Partial Onset Seizures 70 TNF Tumor Necrosis Factor 70 novel VDA molecule 70 Blood Thinner 70 Renal Impairment 70 HDAC Inhibitor 70 Double Blind Placebo 70 Novel Therapeutic 70 Personalized Immunotherapy 70 Bivalirudin 70 5 FU leucovorin 70 Metabolic Disorder 70 Liver Injury 70 Meta Analysis 70 Novel Compound 70 Chronic Myelogenous Leukemia 70 Skeletal Muscle 70 Xcytrin R 70 Hydrochlorothiazide Tablets 70 Tipranavir 70 Interferon Alpha 70 Inhalation Aerosol 70 Milestone Payment 70 Vaginal Gel 70 Sagent Pharmaceuticals Announces 70 J Allergy Clin 70 Immunosuppressant 70 Telaprevir VX 70 ARIXTRA R 70 Develop Novel 70 Initiates Phase 70 Thrombotic 70 Experimental Vaccine 70 Treat Heart Failure 70 Stomach Cancer 70 Submits IND 70 Embolic Protection 70 Significantly Reduced 70 Therapy Reduces 70 imatinib Gleevec ® 70 Beneficial Effects 70 Monoclonal Antibody 70 Multicenter Study 70 Idiopathic Pulmonary Fibrosis 70 Double Blind Randomized 70 Breast Cancer Cells 70 Therapy Improves 70 Oral Cladribine 70 Naive Patients 70 Atopic Dermatitis 70 Antiviral Activity 70 Reduces Risk 70 Vaccine Candidate 70 Symptom Relief 70 aripiprazole Abilify 70 Receives Approvable Letter 70 5q MDS 70 Advanced Ovarian Cancer 70 Investigational Oral 70 Smallpox Vaccine 70 Systemic Delivery 70 Primary Hypercholesterolemia 70 Decompensated Heart Failure 70 Acute Pancreatitis 70 FASLODEX 70 Remission Maintenance 70 Increased Mortality 70 gefitinib Iressa 70 Successfully Treats 70 Protein Linked 70 Potent Antiviral Activity 70 IIa Clinical Trial 70 Phase III Clinical Trials 70 J Shoulder Elbow 70 essential thrombocythemia ET 70 Ebola Vaccine 70 Kit CD# positive 70 Kidney Transplant Recipients 70 Statin Therapy 70 Phospholipase A2 70 Lung Injury 70 Bucindolol Based 70 CYT# potent vascular disrupting 70 Receives CE Marking 70 Ridaforolimus 70 Randomized Double blind 70 Azacitidine 70 Virus Infection 70 Moxifloxacin 70 Shingles Vaccine 70 Receives Orphan Drug 70 Atypical Antipsychotic 70 induce orthostatic hypotension 70 hyperphenylalaninemia HPA due 70 Fludara ® 70 Myelodysplastic Syndrome 70 Vildagliptin 70 Breast Cancer Patients 70 Myocardial Infarction Study 69 Chronic Lymphocytic Leukemia CLL 69 RNAi Therapeutics 69 Non Responders 69 Randomized Double Blind Placebo 69 CYP#A# substrate 69 Platinol ® 69 Cilostazol 69 metastatic neuroendocrine tumors 69 CLARITY TIMI 69 Complete Remission 69 Fluticasone 69 STELARA TM 69 Multicenter Randomized 69 Improve Outcomes 69 See WARNINGS 69 Antiviral Drugs 69 cetuximab Erbitux R 69 Bipolar Depression 69 Alemtuzumab 69 Desvenlafaxine Succinate 69 Antipsychotic 69 Acute Attacks 69 Randomized Evaluation 69 Reports Preclinical Data 69 Disease Modifying 69 Therapeutic Vaccine 69 Telbivudine 69 Seasonal Influenza Vaccine 69 Bronchodilator 69 Hematopoietic Stem Cell Transplantation 69 ALN HPN 69 Antiplatelet Therapy 69 Lung Cancers 69 Completes Dosing 69 Stent Implantation 69 Irinotecan 69 Hepatocellular 69 ACTEMRA TM 69 J Am Acad 69 Perifosine KRX 69 Therapy Evaluation 69 Aggressive Prostate Cancer 69 Non Inferiority 69 Natalizumab 69 thalidomide Thalomid 69 Telithromycin 69 Sirolimus Eluting Stent 69 Iron Overload 69 Bloodstream Infections 69 Renal Artery 69 Inhalation Solution 69 Multicenter Trial 69 Generic Versions 69 Novel Vaccine 69 Neuroendocrine Tumors 69 Diagnostic Tests 69 Pancreatic Adenocarcinoma 69 Seasonal Allergic Rhinitis 69 Genetic Tests 69 Oral Formulation 69 icatibant 69 PEGylated anti 69 Bosentan 69 Gene Variation 69 MMR Vaccine 69 Gastrointestinal Stromal Tumors 69 Zoledronic Acid 69 Anticancer Drugs 69 Kamada AAT 69 MEK Inhibitor 69 Pivotal Phase II 69 Inflammatory Arthritis 69 Camptosar ® 69 Presents Preclinical 69 Tumor Targeting 69 recurrent glioblastoma multiforme 69 Premenopausal Women 69 AVAPRO 69 Gemzar ® 69 Cyclophosphamide 69 Medullary Thyroid Cancer 69 acetonide FA 69 Enoxaparin 69 sunitinib Sutent ® 69 Inhibits 69 TRANSDUR ™ 69 LENALIDOMIDE 69 Renal Cell Carcinoma RCC 69 Treatment Regimen 69 systemic juvenile idiopathic 69 Test Detects 69 relapsed MM 69 Novel Mechanism 69 Commence Phase 69 Cholesterol Drugs 69 Hepatotoxicity 69 Universal Flu Vaccine 69 Myocardial Ischemia 69 Pirfenidone 69 Insulin Resistance 69 Anticancer Agent 69 C1 Inhibitor 69 Sapacitabine 69 Receives Fast Track 69 Aliskiren 69 Community Acquired Pneumonia 69 Carboplatin Paclitaxel 69 Chemotherapeutic Agents 69 Dasatinib 69 Heart Transplant Recipients 69 Announces FDA Clearance 69 Taro Receives 69 oncolytic virus therapies 69 Migraine Drug 69 nilotinib Tasigna 69 Diabetic Neuropathic Pain 69 Genital Herpes 69 Malaria Vaccine 69 Acute Exacerbations 69 Submits Response 69 Placebo Controlled Study 69 Angiox ® 69 Lung Cancer Survival 69 Adalimumab 69 Desvenlafaxine 69 reduce serum phosphate 69 erlotinib Tarceva ® 69 FOLOTYN ® 69 Advanced Pancreatic Cancer 69 Arch Facial Plast 69 Blood Cancers 69 Granulocyte Colony Stimulating Factor 69 lexidronam injection 69 Circulating Tumor Cells 69 Maleate 69 Aneurysm Repair 69 Cervical Dysplasia 69 Receives Marketing Authorization 69 SNT-MC#/idebenone 69 Eculizumab 69 Immunosuppression 69 Cancer Treatments 69 Viral Load 69 Lymphocytic 69 Protease Inhibitors 69 Cholesterol Lowering 69 Percutaneous Tibial Nerve Stimulation 69 Hedgehog Pathway 69 Golimumab 69 Neovascular Age Related Macular 69 Radical Prostatectomy 69 Invasive Fungal Infections 69 Radiofrequency Ablation RFA 69 Peripheral Arterial 69 Orphan Status 69 Therapeutic Potential 69 Late Breaker 69 CCX# B 69 Therapy Shows Promise 69 NAVISTAR R 69 Lymph Node 69 Hepatitis C Patients 69 Sevelamer 69 Venous Thrombosis 69 Smooth Muscle 69 Asthma Treatment 69 Prolongs Life 69 J Clin 69 vapreotide acetate 69 Cardiogenic Shock 69 AVASTIN 69 Antiviral Therapy 69 Dalbavancin 69 CYP#A# CYP#D# 69 Progenitor Cells 69 Subtypes 69 Bare Metal Stent 69 Parenteral Nutrition 69 Increased Risk 69 atypical Hemolytic Uremic Syndrome 69 myocardial infarction ventricular fibrillation 69 Adjunctive 69 Paliperidone Palmitate 68 Gastric Ulcers 68 Kuvan R 68 pioglitazone hydrochloride 68 BioElectronics Announces 68 Anti Inflammatory Drug 68 Peginterferon alfa 2b 68 Vaccine Adjuvants 68 Vitrasert R 68 Oral Insulin 68 BARACLUDE R 68 Colorectal Adenomas 68 Antidepressant Drug 68 Prospective Multicenter 68 Cardiac Resynchronization 68 Mouse Models 68 CHMP Opinion 68 Announces Tentative Approval 68 BARACLUDE ® 68 Metabolic Efficiency 68 Signaling Pathway 68 Pemetrexed 68 Renal Anemia 68 Laryngeal Cancer 68 Randomized Phase III 68 severe oral mucositis 68 Oral Interferon 68 Vidaza R 68 ORLive Presents 68 Rectal Cancer 68 Randomised 68 PEGylated Fab fragment 68 Adenoma 68 Posaconazole 68 Randomized Trials 68 Cyclooxygenase 2 68 PEGylated interferon beta 1a 68 Chemotherapy Induced 68 Parnate 68 candesartan cilexetil 68 Albuferon TM 68 Advanced Solid Tumors 68 Cardiol 68 Adefovir 68 Less Invasive 68 Topical Treatment 68 Xelox 68 Psoriasis Patients 68 ISTODAX ® 68 Bevacizumab 68 Phase III Pivotal Trial 68 Prospective Randomized Trial 68 NSABP B 68 Recurrent Ovarian Cancer 68 Pegylated 68 Androgen Deprivation Therapy 68 Synthetic Peptide 68 Rheumatoid 68 beta 1a 68 Synta Announces 68 Adult Stem Cell Therapy 68 Erectile Dysfunction Drug 68 abacavir sulfate lamivudine 68 Adenoviral 68 Receptor Agonist 68 Cancer Recurrence 68 Therapeutic Efficacy 68 Genetic Variant 68 Receptor Antagonist 68 Valsartan 68 Ziprasidone 68 Paclitaxel Carboplatin 68 Skin Lesions 68 kidney urologic 68 Regeneron Pharma 68 Minimally Invasive Treatment 68 Neulasta R 68 alfa 2b 68 RE MODEL 68 Chemotherapy Regimen 68 PEG IFN 68 evaluating tivozanib 68 Diabetic Kidney Disease 68 Novel Therapies 68 REG1 Anticoagulation System 68 Am J Obstet 68 Fludarabine 68 Randomised Controlled Trial 68 Myocardial Perfusion Imaging 68 AVI BioPharma Announces 68 Topline Results 68 Ecallantide 68 Cimzia ® certolizumab pegol 68 Obesity Linked 68 Abciximab 68 Interferon Alfa 68 Patent Covering 68 Intervention Effectiveness 68 Stent Placement 68 sorafenib tablets 68 colesevelam HCl 68 Sirolimus Eluting 68 Biomarker Study 68 Collaborators Present 68 Vascular Disrupting Agent 68 number NCT# ClinicalTrials.gov 68 Bendamustine 68 PROMUS TM 68 Eur J 68 interferon gamma 1b 68 Rotavirus Vaccines 68 BioSante Pharmaceuticals Announces 68 Humanized Anti 68 Generalized Anxiety Disorder 68 leukemia AML 68 Long Term Survival 68 Bone Marrow Transplants 68 Oral Spray 68 Heartburn Drugs 68 Demonstrate Significant 68 phenyl salicylate methylene blue 68 Anti CD# Antibody 68 Commercialize Novel 68 Non Invasive Treatment 68 Microalbuminuria 68 Receive Milestone Payment 68 Targeted Therapy 68 Maribavir 68 HBeAg + 68 Lanthanum Carbonate 68 Hip Fractures 68 SinuNase TM 68 Factor Receptor 68 Phase Ib IIa 68 Gene Mutation Linked 68 Tuberculosis Vaccine 68 Lymphoid 68 Efficacious 68 Portal Hypertension 68 EURIDIS 68 Daptomycin 68 Begins Clinical Trial 68 Lenalidomide 68 Enrolls First 68 Therapeutic Antibody 68 ZOLINZA 68 MKC# MT 68 Fulvestrant 68 diarrhea predominant irritable 68 Shows Statistically Significant 68 Carbidopa Levodopa 68 Significant Reduction 68 Proc Am Soc 68 Randomized Controlled Trial 68 Known hypersensitivity 68 INSPIRE Trial Phase III 68 unfractionated heparin UFH 68 IL# PE#QQR 68 Hodgkin lymphoma HL 68 Sustained Reduction 68 Multicenter Phase 68 Organ Rejection 68 dalteparin 68 docetaxel Taxotere ® 68 Nanoemulsion 68 By JENNIFER LEARN 68 Antihypertensive 68 Angioedema 68 Serostim ® 68 Nymox NX 68 Left Ventricular Hypertrophy 68 Interferon beta 1b 68 Hepatitis C Treatment 68 Val HeFT 68 Xeloda ® 68 Adverse Event 68 Inflammatory Disease 68 Preterm Delivery 68 Treatment Outcome 68 LymphoStat B TM 68 Predict Dementia 68 Clinical Evaluation 68 Bepreve TM 68 Obstet Gynecol 68 Sleep Disturbances 68 XYOTAX TM 68 ODT metoclopramide HCl PEPCID 68 Cholinesterase Inhibitors 68 STRIDE PD 68 HCV Genotype 68 PKC# 68 Effective Than 68 Begin Clinical Trials 68 Virus Linked 68 Taxane 68 Valvular 68 Lymphoma Patients 68 Cognitive Function 68 Announces Poster Presentations 68 Dupuytren Contracture 68 Genetic Predisposition 68 Inflammatory Diseases 68 Amgen Neulasta R 68 Asthma COPD